Your search for dasatinib returned 36 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for dasatinib returned 36 results

Sort Results:

Relevant Recent

Optimal Dose Suggested for Dasatinib in Ovarian Cancer

A Phase 1 trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer.
ASH 2011

HyperCVAD Plus Dasatinib Effective in Patients with Ph+ ALL or CML-LB

Combining the hyperCVAD regimen with dasatinib, a dual Scr and BCR-ABL kinase inhibitor, is effective in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) or chronic myeloid leukemia in the lymphoid blast phase (CML-LB), according to investigators at the 53rd American Society of Hematology Annual Meeting and Exposition.
ASCO 2011

Dasatinib Shows Superior Efficacy and Acceptable Tolerability, Supporting First-Line Use in Newly Diagnosed CML-CP

The BCR-ABL kinase inhibitor dasatinib achieved significantly higher and faster rates of complete cytogenetic response and major molecular response than imatinib as first-line treatment in patients with previously untreated chronic myeloid leukemia, according to 24-month follow-up results from the randomized Phase 3 DASISION trial reported at the American Society of Clinical Oncology's 2011 Annual Meeting.
ASH 2010

Therapeutic Potential of Bosutinib Observed in Patients With Chronic-Phase Chronic Myeloid Leukemia Following Failure of Second-Line Therapy With Dasatinib or Nilotinib

Bosutinib has therapeutic potential in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic-phase (CP) chronic myeloid leukemia (CML) with resistance to—or, particularly, intolerance to—other second-generation tyrosine kinase inhibitor (TKI) therapies, results of an open-label, phase 1/2 study presented at the 52nd American Society of Hematology Annual Meeting and Exposition has found.
ASH 2010

Follow-Up Results Support Potential Use of Dasatinib As Initial Therapy for Patients Newly Diagnosed With Chronic-Phase Chronic Myeloid Leukemia

Dasatinib continues to demonstrate superior efficacy compared with imatinib as initial treatment for patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP), results of an 18-month follow-up of the phase 3 DASISION comparative trial have shown. The data was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.
Drug Monograph


Dasatinib 20mg, 50mg, 70mg, 80mg, 100mg, 140mg; tabs.
Drug Monograph Updates

February 2019 Recap of Drug Updates

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of February. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on Key: D=Dosing,…